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ABSTRACT 
 
 
 The current clinical chemotherapy agents are not ideal for breast cancer as they 
are not curative, but only provide a modest extension of survival with sometimes a 
severely adverse effect on the patient’s quality of life. There is, therefore, an urgent need 
to search for new and more effective anti-breast cancer drugs. However, the existing 
screening system is inefficient and time-consuming despite the extremely large amount of 
small molecule compounds in database currently available, and thereby hindering the 
effort for selecting new and effective anti-cancer drugs. 
 
 The majority of locally advanced solid tumors contain regions of reduced oxygen 
availability. Hypoxia has been identified as a major negative prognostic factor for tumor 
progression and resistance to anti-cancer therapies. Hypoxia promotes cell proliferation, 
immortalization, genetic instability, and induces cells to switch their methods of glucose 
metabolism, a normal response to proliferation. In animal models, HIF-1 (a heterodimer 
composed of one of the three alpha subunits-HIF-1α, HIF-2α or HIF-3α- and one 
constitutively expressed HIF-1β subunit) overexpression is associated with increased 
tumor growth, vascularization, and metastasis. The goal of this project, therefore, is to 
identify a novel compound with anti-HIF-1α activity, using an efficient high-throughput 
screening system that has the capability to screen large numbers of potential anti-cancer 
drugs.  
 
Because HIF-1α is the transcriptional regulator for a group of malignant-pathway 
related genes (including VEGF) and it promotes the tumor progression and metastasis, 
identification of novel anti-HIF-1α agents will lead to the blocking of HIF-1α-mediated 
“switch-on” function for those malignant-pathway related genes, and thus the suppression 
of VEGF signaling pathway and breast cancer progression and metastasis. 
 
To screen for effective anti-HIF-1α compounds, human breast cancer cells treated 
with or without candidate compounds were transfected with a chimeric construct 
containing a VEGF promoter fused to a reporter gene luciferase (pVEGF-Luc), followed 
by incubation in the hypoxic conditions. As the HIF-1α-mediated VEGF transactivation 
was reflected by increased luciferase activity, the potential anti-HIF-1α effect of the 
compound were identified by its significant reduction of luciferase activity compared to 
the untreated control. 
 
 Given its potential for systemic administration and targeting, an anti HIF-1α 
compound could prove useful as a therapy against breast carcinoma growth and invasion. 
We propose that down regulation of HIF-1α by anti HIF-1α drug will lead to a decrease 
in the level of hypoxia-induced genes including VEGF, subsequently resulting in the 
inhibition of tumor growth, decrease metastasis to surrounding organs, block tumor 
metastasis and increase survival in breast carcinoma animal model. 
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CHAPTER 1.    INTRODUCTION 
 
 
Background 
 
In 2010, an estimated 210,000 cases of invasive breast carcinoma were diagnosed 
in the USA [1]. Next to lung cancer, breast cancer is the second most common cancer 
worldwide, the fifth most common cause of cancer death, the most common malignancies 
in women, and the number one cause of cancer death in women between 20 and 59 years 
of age in the United States. An ever-increasing rate of incident cases of breast cancer has 
also been observed in 2007, where more than 40,000 women died from breast cancer in 
the United States. In 2008, an estimated 12.5% women were expected to develop breast 
cancer during their lifetime, with approximately 54 000 new cases of in situ breast 
carcinoma diagnosed in 2010 in the USA [1, 2]. In terms of global burden, no other form 
of cancer surpasses breast cancer, with the annual cost of treatment for breast cancer 
patients exceeded $8 billion in 2010 [3]. The etiology of breast cancer is somewhat 
complex-both environmental and genetic factors play a contributory role in its 
development; an exigent disease to treat due to its heterogeneous characteristic 
molecularly, clinically, and pathologically [4].  
  
The discovery of molecular changes linked with the different stages of breast 
cancer progression has been a crucial challenge in breast cancer research for many years. 
Despite the discovery of new therapies and drug combinations that has led to the 
improvement in the prognosis of the disease, the cure remains elusive. Latest advances 
stemming from better understanding of the biology and the molecular transformations in 
these cells, coupled with improved technologies and techniques however have led to a 
better understanding of the intricate genetic and molecular biological inter-relationships 
of the different phases of breast cancer progression. Together, this has led to the design of 
therapies that target specific aspects of the disease. Some of these agents include 
angiogenesis inhibitors which targets angiogenesis, a critical step for the progression of 
breast cancer. The onset of angiogenesis is orchestrated by various physiological and 
pathological stimuli, chief among these is hypoxia [5-7]. 
 
 
Role of Hypoxia in Human Breast Carcinoma Cell Lines 
 
For over four decades, researchers have identified the regions of hypoxia within 
many solid tumors, and over time its role in tumor progression increasingly came to light 
[8]. The degree of hypoxia is observed to be inversely correlated with prognosis in a 
number of tumor types [9, 10]. A prevalent condition in tumors, hypoxia stimulates an 
extensive range of responses in cells and tissues including metastases, therapeutic 
resistance, and poor patient survival; hypoxic cells are more invasive, resistant to 
apoptosis, and genetically unstable. About 50% of breast cancer cells are hypoxic, and 
approximately 30% of the tumors have regions less than 0.3% median oxygen 
concentration, while normal breast tissues has been observed to have concentrations 
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higher than 9%. Therefore these cells devise physiological and pathophysiological 
methods of adaptation to hypoxia as a vital step for survival and growth. This 
phenomenon, a common hallmark of carcinomas, presents breast cancer cells with a high 
level of resistance to conventional radiation therapy and chemotherapy [10]. 
 
As these cells get exposed to repeated periods of hypoxia, they are compelled to 
adapt to this environmental stress, and this eventually may lead to induced apoptosis in 
response to hypoxia. Whether cells resort to apoptosis or adapt to hypoxia and survive, 
largely depends on the severity of hypoxic environment. An absence of nutrients or an 
insufficient amount will make the cells become necrotic; an alternative to undergoing 
energy dependent apoptosis if sufficient nutrients were available. Hypoxia inducible 
factor 1 (HIF-1), a family of transcription factors critically implicated in the response of 
mammalian cells to low oxygen levels, has been identified as the main regulator of this 
process. It initiates apoptosis by stimulating the synthesis of high concentrations of 
proapoptotic proteins, as well as targeting other genes. These resistant cells usually have 
a more aggressive phenotype and will often demonstrate a diminished response to 
established treatment [11-13]. This has prompted a search for new treatment protocols 
targeting hypoxic tumors [14]. The exponential growth of a tumor leads to the rapid 
depletion of the available nutrients and oxygen. The ultimate survival and progression of 
the tumor will therefore depend on its ability to instigate new vascularization in order to 
replenish the levels of nutrients and oxygen [15].  
 
One key outcome arising from these responses and adaptations related to tumor 
evolution includes: a tilt in the balance between pro and anti-apoptotic factors to promote 
survival [16]. In the last couple of years, researchers have generated several strategies to 
target tumor hypoxia [17]. However, it was not until the discovery of Hypoxia Inducible 
Factors (HIF-1s), one of the primary regulators of hypoxia-responsive pathways, that a 
molecular target of hypoxia was recognized, which can be exploited for the development 
of cancer drugs [18-20]. 
 
 
HIF-1 
 
HIF-1 is a transcription factor, and a heterodimer, consisting of one of the three 
alpha subunits (HIF-1α, HIF-2α or HIF-3α) and one constitutively expressed HIF-1β 
subunit [18]. The protein was initially described in 1995 while researchers were 
investigating the hypoxic induction of the EPO gene. It was purified and revealed to be 
composed of two basic helix-loop-helix (bHLH) proteins of the PAS family - HIF-1α and 
HIF-1β (Figure 1-1). Each exists in various forms with molecular masses of 120–130 
KDa and 91–94 KDa respectively [16]. HIF-1α, recognized as the dimer distinctively 
associated with the transcription of the hypoxia-inducible genes, is the newly 
characterized of the two.HIF-1β, on the other hand, had previously been known as the 
aryl hydrocarbon nuclear receptor translocator (ARNT), which is dimerized with the aryl 
hydrocarbon receptor. Further studies and experiments revealed other members of this 
family, such as HIF-2α (also known as endothelial PAS protein-1) [22, 23] and HIF-3α 
[24]. 
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Figure 1-1. Schematic structure of HIF-1. 
 
Both the α and β subunits belong to the basic helix–loop–helix (bHLH)–PAS (PER, 
ARNT, SIM) protein family domains, which are involved in dimerization and DNA 
binding. The oxygen-dependent degradation domain (ODD) regulates the stability of the 
α subunit and contains a domain for binding to the von Hippel–Lindau (pVHL) E3 
ubiquitin ligase. The α subunit consists of 826 amino acids, and contains two 
transactivation domains (TAD), the N- and C-terminus activation domains, while the β 
subunit contains one. Transcriptional activity is regulated via domains, also several 
co-activators, including p300/CBP, have been identified as interacting with the TAD-C 
[21]. 
 
  
bHLH PAS TADN
TAD
C
COOHNH2
HIF-1α
bHLH PAS TAD COOHNH2
HIF-1β
ODD
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Just like HIF-1α, HIF-2α is also tightly regulated by low oxygen tension and its 
complex, but HIF-1α seems to be party directly implicated in hypoxic gene regulation 
[24]. Some have suggested that HIF-3α, though homologous to HIF-1α, might act as a 
negative regulator of hypoxia-inducible gene expression [25].  
 
HIF-1 binds to the HRE DNA center recognition sequence (5′-RCGTG-3′), and 
plays a central role in tumor progression through the initiation and regulation of the 
transcription of a number of genes essential for tumor adaptation to hypoxia and has been 
implicated in major aspects of cancer biology, including immortalization, cellular 
dedifferentiation, genetic instability, vascularization, etc [21, 26-30], making it a 
principal target for anti-cancer therapy. It has also been described as unique in its 
expression and function in various cells of the tumor microenvironment-another feature 
that makes it an attractive target for therapy [31-33]. 
 
Generally, the amount of HIF-1α determines the formation and transcriptional 
activity of HIF-1, and its expression is strongly under the control of the cell’s oxygen 
tension [21]. HIF-1α has a short half-life under normoxic conditions, making it a very 
unstable protein. The HIF-1α protein is constantly subjected to strong oxygen-dependent 
proteasomal degradation in both the cytoplasm and nucleus, while the β subunit is 
relatively unaffected by the oxygen concentration [34]. Additionally, as published by 
Chun et al, HIF-1α is also regulated by a range of other stimuli, including transition 
metals, nitric oxide, reactive oxygen species, growth factors, and mechanical stresses [35, 
36]. 
 
 
HIF-1 Pathway 
 
In the presence of oxygen (O2), HIF-1α is modified post-translationally by prolyl 
hydroxylase at specific proline residues (Pro402, Pro564) within the ODD domain, 
facilitating its interaction with the von Hippel–Lindau (VHL) complex [37]. VHL is a 
component of a larger complex that consists of a ubiquitin-conjugating enzyme (E2). 
This complex prompts the ubiquitylation (Ub) of HIF-1 α [38, 39], rendering HIF-1α a 
target for degradation. In hypoxia, HIF-1α cannot be modified by prolyl hydroxylase, 
leading to the protein being stabilized. The stabilized HIF-1α is translocated to the 
nucleus, where, subsequent to dimerization with HIF-1β and recruitment of numerous co 
activators they both bind to the same hypoxia responsive element (HRE) at the target 
gene loci and activate transcription of target genes [40] (Figure 1-2). 
 
 HIF-1 not only mediates cellular adaptation to hypoxia by regulating biological 
processes essential for cell survival, it also participates in several cellular processes that 
take place under normoxic conditions, such as normal tissues growth, death or survival, 
immune responses, and the adaptation to mechanical stresses. The regulation of HIF-1 in 
these cases does not rely on oxygen tension, but is coordinated by a range of stimuli. The 
basal level of HIF-1α expression in tumor cells is also noticeably increased as a result of 
somatic mutations that activate oncogene products or inactivate tumor suppressors [17]. 
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Figure 1-2. Schematic of HIF-1α pathways and downstream activity. 
HIF-1α is either degraded in the presence of O2 (right pathway) or is stabilized in 
hypoxia, heterodimerizes with HIF-1β, and binds to hypoxia response element domains 
(left pathway) to transcribe numerous proteins. 
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Implications of HIF-1α Activation in Breast Cancer Cells 
 
HIF-1 has been reported in normoxic tissues, which implies it may be essential for 
preserving the basal expression of the vital genes it regulates. Furthermore, the extensive 
accumulation and nuclear targeting of HIF-1 has also been reported in ischemic tissues 
[41]. Recent studies suggest that different target genes could be affected by HIF-1α under 
normoxic conditions with differing physiological roles from those induced by hypoxia 
[42]. There is a positive correlation between the expression levels of HIF-1 in the 
biopsies of various solid tumors with tumor aggressiveness, vascularity, treatment failure, 
and mortality. Furthermore, tumor growth and angiogenesis in grafted tumors rely to a 
reasonably high degree on the HIF-1 activity or the expression level of HIF-1. 
Consequently, HIF-1 enhances the process of angiogenesis during tumor development by 
inducing the expression of the gene products that promote angiogenesis, such as vascular 
endothelial growth factor, basic fibroblast growth factor, and angiopoietin 2. [41]. It also 
supports the survival of tumor cell under hypoxic conditions by means of the expression 
of gene products that advance anaerobic ATP synthesis, such as glucose transporters [26, 
43, 44]. 
 
 As stated above several biological pathways like angiogenesis, glycolysis, 
apoptosis and cell cycle are regulated by HIF-1α. Some of these pathways, including 
angiogenesis, decreased apoptosis, increased cell cycling, loss of cell cycle arrest, often 
transform the tumor to a more aggressive phenotype [45]. Angiogenesis is vital for the 
growth and metastasis of solid tumors, and the inhibition of angiogenesis is seen as a 
prospective strategy for cancer treatment [46]. Vascular endothelial growth factor 
(VEGF), an angiogenic factor, plays a pivotal role in tumor angiogenesis [15, 46]. It is a 
dimeric glycoprotein secreted by cells that is cable of inducing permeability and 
angiogenesis in tumor-associated blood vessels [47]. VEGF and its receptors are widely 
regarded as key targets for antiangiogenic therapy because of the role they play in 
angiogenesis. A series of investigations have revealed a number of antibodies and soluble 
proteins that interact with VEGF and its receptors that can come into play as 
antiangiogenic therapies for solid tumors [48]. 
 
Presently, numerous drugs have made it to clinical trials as anticancer agents 
based on their ability to inhibit angiogenesis [19]. Some researchers have however 
expressed some reservations about this approach. First of such is the fact that targeting 
angiogenesis might inadvertently screen for cancer cells that are adapted to hypoxic 
conditions, since they possess the greatest likelihood to survive a reduction in perfusion 
[19]. Secondly, besides angiogenesis, another vital adaptation process for cell survival 
under hypoxia is changes in energy metabolism which may prolong the life span of the 
tumor beyond its expected death [49]. Therefore, inhibiting angiogenesis directly and 
specifically will only inhibit one of the arrays of factors that enhance tumor growth. 
Scientists have proffered that since compromised glucose uptake and metabolic 
adaptation is also responsible for the reduced tumorigenicity, any anticancer strategy that 
does not target the metabolic activity of the tumor will not be effective in halting the 
tumor progression [50]. 
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As a result of this, the consequences of inhibiting HIF-1 should be multiple since 
multiple targets would be hit by inhibiting a variety of genes that work in concert to 
advance the expansion of the tumor. Therefore, inhibition of HIF-1 activity, rather than 
angiogenic factors directly, could represent an important and better strategy of 
anti-angiogenesis therapies. In fact many novel therapeutic agents that target 
signal-transduction pathways that have antiangiogenic effects, may be due in part to the 
fact that inhibition of that signal-transduction pathways results in decreased levels of 
HIF-1α [19]. 
 
Ryan, et al. were the first to demonstrate in studies that genetic deletion of HIF-1 
can retard tumor growth. It has since then been shown that inhibition of HIF-1 will lead 
to inhibition of tumor expansion by decreasing pro-angiogenic gene expression [51]. It 
follows, therefore, that since angiogenesis is often stimulated by hypoxic conditions via 
VEGF synthesis, and since HIF-1(which activity is dependent upon the level of available 
HIF-1α) is a hypoxia activated transcription factor that can regulate VEGF synthesis, 
HIF-1α can be a potent mechanism for treating a broad range of hypoxia-related 
pathologies [52].  
 
 
Research Objective and Specific Aims 
 
 
Objective 
 
 The objective of this proposal was to use a synthesized novel inhibitor of HIF-1α 
and the downstream target genes to maximally reduce tumor vascularization. Small 
molecule HIF-1 inhibitors represent potential drug leads that suppress tumor growth and 
enhance chemotherapy/radiation by inhibiting hypoxia induced gene expression. Our 
hypothesis is that a pharmacological drug that inhibits VEGF signaling pathway will 
effectively inhibit angiogenesis, which contributes to tumor growth and metastasis. 
Towards achieving this goal, we set the following specific aims: 
 
 
Specific Aim 1 
 
To identify the novel compounds that effectively inhibits VEGF signaling 
pathway. Since HIF-1α is the master regulator which controls VEGF expression, a library 
of several hundreds of small molecule compounds were screened based on their 
anti-HIF-1α activity. 
 
 
Specific Aim 2 
 
To determine whether the identified potentially therapeutic compounds inhibit 
levels of HIF-1α protein produced by breast cancer cells growth in vitro, and investigate 
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the potential growth inhibition of breast cancer cells by the potential therapeutic 
compounds. 
 
 
Specific Aim 3 
 
To determine whether potential therapeutic compounds inhibit tumor cell-induced 
angiogenesis. The effects of the most potential therapeutic compound on angiogenesis 
will be evaluated in in vitro angiogenic assays.  
 
 
Specific Aim 4 
 
To determine whether the potential therapeutic compounds suppress breast tumor 
metastasis, and explore their possible mechanism of anti-cancer action in vitro. 
 
For most of the experiments, we used the MDA-MB-231 cell line, which is a 
human breast cancer cell line, because of its invasive phenotype, high potency of 
metastasis, and relatively high colony forming efficiency. The other cell line selected was 
the JygMC(A) cell line, a mammary carcinoma in the fat pads of a female JYG mouse 
that has the capacity to metastasize efficiently to sites affected in breast cancer.  
 
We initially set out to confirm by western blot that:  
 
a) Hypoxia condition is associated with an increased expression of HIF-1α by 
validating HIF-1α expression in MDA-MB-231 and JygMC(A) cell lines, and 
the induction of HIF-1α protein in MDA MB cell line is at its highest level at 
18 hr in hypoxia (Figure 1-3). 
b)  Hypoxia condition is associated with an expression of two of HIF-1 target 
genes (GLUT-1 and VEGF) in MDA-MB-231 cells (Figure 1-4). 
c) HIF-1α degrades under normoxia condition in a time dependent manner, with 
a half-life of ~5 mins (Figure 1-5). 
 
 As a result of its role in angiogenesis, VEGF and its receptors have become main 
targets for antiangiogenic therapy. Since HIF-1 is a hypoxia-activated transcription factor 
that can regulate VEGF synthesis, and HIF-1 activity is dependent upon the level of 
available HIF-1α, a rationale is therefore provided for developing a novel agent aimed at 
targeting the hypoxic fraction of solid tumors and HIF-1-dependent responses. The 
discovery and development of novel agents targeting hypoxia signaling pathways is a 
crucial area of developmental therapeutics that continues to grow. 
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Figure 1-3. Hypoxia is associated with an increased expression of HIF-1α. 
 
Effects of Hypoxia on the protein expressions of HIF-1α were analyzed by western 
blotting. At 18 hr hypoxic incubation, levels of HIF-1α maximally increased in both 
MDA-MB-231 and JygMC(A) cells. 
 
 
 
 
 
 
Figure 1-4. Hypoxia is associated with an increased expression of HIF-1α 
inducible genes. 
 
Effects of hypoxia on HIF-1α inducible genes were analyzed by western blotting. At 18 
hr hypoxic incubation, levels of HIF-1α and VEGF protein increased, while levels of Glut 
1 protein peaked at 12 hr hypoxic incubation. 
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Figure 1-5. HIF-1α degrades under normoxia condition in a time dependent 
manner. 
 
After a 1 hr incubation in a hypoxic environment, MDA-MB-231 cells were re 
oxygenenated (20%) for different periods of time. 
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CHAPTER 2.    IDENTIFICATION OF NOVEL COMPOUNDS THAT INHIBIT 
VEGF SIGNALING PATHWAY 
 
 
Introduction 
 
An increasing number of anticancer agents have been discovered to inhibit HIF-1 
activity. The mechanism of action for many of these agents involves the decrease in the 
rate of HIF-1α synthesis, increasing the rate of HIF-1α degradation, or both. These 
compounds perform this through the reduction of HIF-1α mRNA or protein levels, 
modulation of HIF-1 DNA-binding activity, or HIF-1-mediated transactivation of target 
genes [16]. Already, several nonselective inhibitors, which indirectly target signaling 
pathways upstream or downstream HIF-1 have been discovered to decrease HIF-1α 
protein levels. The prospect of HIF-1α as a target for cancer therapy depends on such 
small molecule inhibitors of HIF-1 [19].  
 
 
Design and Validation of a High-Throughput Screen System for Potential  
Anti-Cancer Drugs with Anti-HIF-1α Activity 
 
For several years, High-Throughput Screening (HTS), a system that expedites the 
screening of biochemical compound libraries against biological targets, has been 
extensively employed in stem cell research, drug discovery, and development of new 
biomaterials [53]. One of the first cell-based High Throughput Screens -targeting HIF-1 
to be developed and implemented was at the Developmental Therapeutics Program of the 
National Cancer Institute (NCI) at Frederick, where several chemical libraries were 
screened to identify HIF-1 inhibitors [54]. A screen conducted by the NCI comprising of 
approximately 2000 compounds led to the identification of Topotecan, a camptothecin 
analog and topoisomerase I inhibitor, as one of the earliest and potent inhibitor of HIF-1α  
protein translation [54]. These cell-based HTS take advantage of the ability of HIF-1 to 
activate transcription of reporter genes either when cells are subjected to hypoxic 
environment-typically 0.1–1% O2 - or when treated with HIF-1α activators, such as 
Dimethyloxalylglycine (DMOG) - a cell permeable prolyl-4-hydroxylase inhibitor, 
which upregulates HIF [55]. 
 
As reviewed in Melillo, 2006, most of the HIF-1 inhibitors described in several 
papers have been identified either in cell-based screens or by empirical discoveries during 
evaluation of HIF-1 activity in cultured cancer cell lines [18]. They rely on the ability of 
HIF-1 to bind a recognition sequence in the DNA (the hypoxia responsive element 
(HRE)) and activate transcription in a sequence-specific fashion [56]. One advantage of 
cell-based HIF-1–targeted HTS is the prospect of discovering small molecules that inhibit 
unidentified components of the hypoxic cell signaling pathway. However, several 
extensive mechanistic investigations are frequently required to validate any potential anti 
HIF-1 compound identified in the primary screen [57]; therefore more experiments are 
usually expected and routinely performed for the validation purposes.  
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Experiments previously conducted using transiently transfecting cancer cell lines 
with constructs containing reporter genes under control of multiple copies of HRE, have 
confirmed nearly all mammalian cells respond to hypoxia with induction of HIF-1 
transcriptional activity [58]. In the screens, a reliable reporter gene is used, and luciferase 
is commonly used for screening purposes because it can be easily measured in high 
throughput assays as well as in animal models by noninvasive imaging of bioluminesce 
[8]  
 
We designed a high-throughput screening to identify compounds with anti HIF-1α 
activity (Figure 2-1). A typically suggested safe guard against false results in such 
procedure is the inclusion of control cell lines and/or plasmids in which luciferase is 
constitutively expressed to exclude nonspecific effects, given that HIF-1–targeted HTS 
depend on synthetic promoters or inhibitors driving or suppressing the expression of a 
reporter gene [8]. A reporter plasmid was therefore transiently transfected into a human 
breast cancer cell line -MDA-MB-231 cell line or the mouse mammary carcinomas, 
JygMC(A). Another safe guard suggested is the inclusion of a known compound that 
inhibits HIF-1 or/and VEGF [8]. Therefore we carried out trial high-throughput screening 
assays with a known anti HIF-1α compound, as a positive control, as we measured the 
activity of luciferase.  
 
One compound that has been found to have potent antitumor activity is YC-1, 
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole, a soluble guanylyl-cyclase stimulator 
(Figure 2-2). Soluble guanylyl cyclase is a receptor for nitric oxide, a molecule that acts 
in a pleiotropic manner in regulating angiogenesis and haematopoiesis. YC-1 was 
originally discovered in Teng’s laboratory [59], and currently, is used as an inhibitor of 
HIF-1α because it has been reported to reduce the protein level of HIF-1α and inhibit the 
expression of hypoxia-inducible genes in cultured hepatoma cells. YC-1 was also found 
to arrest the growth of five xenografted human tumors without inducing noticeable 
toxicity. Furthermore, tumors from YC-1-treated mice showed fewer blood vessels, 
reduced HIF-1α levels, and lower levels of HIF-1-regulated gene transcription. Research 
conducted by Yeo, et al. shows that it inhibits HIF-1α protein stability and transactivation 
of downstream effector genes in cell culture studies [59-60]. It has also been described to 
halt tumor growth by blocking angiogenesis [61]. However, the potential of YC-1 to 
increase bleeding time, cause hypotension, and penile erection, limits its clinical 
applications [62]. 
 
With a positive control established, we then sought to find a functional novel 
inhibitor of HIF-1α through the high-throughput screen of a library of compounds (Figure 
2-3) to identify small molecules inhibiting the HIF-1 pathway (Specific Aim 1). The 
compounds in the library, which share a structural motif with YC-1, were tested for their 
ability to inhibit the hypoxic activation of a VEGF reporter gene under the control of 
hypoxia-responsive elements in breast cancer MDA-MB-231 and JygMC(A) cell lines. 
 
Positive compounds were further validated by a panel of secondary assays. Some 
of the experiments to explicate the mechanism of action of HIF inhibition included 
expression of endogenous HIF-1 target genes (specifically VEGF), western blot analysis  
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Figure 2-1. A simplified algorithm for validation of compounds through the HTS. 
 
 
 
 
 
 
Figure 2-2. Structure of YC-1. 
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Figure 2-3. A representative sample of YC-1 analogues. 
 
Compounds in red displayed poor outcomes as reported by the result of the HTSS, 
compounds in yellow displayed good outcomes, while compounds in green displayed 
superior outcomes. Used with permission from Dr Wei Li, Department of Pharmaceutical 
Sciences, University of Tennessee Health Science Center, Memphis. Tennessee. 
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to measure the levels of HIF-1α protein in cells, and/or Enzyme-linked immunosorbent 
assay (ELISA). A decrease in the levels of HIF-1α protein as confirmed by these 
validations, revealed an impairment of protein translation or an increase of its 
degradation. 
 
 
Materials and Methods 
 
 
Cell Lines and Cell Culture Conditions 
 
RPMI-1640 media was purchased from Gibco BRL (Gaithersburg, MD), and 
Fetal Bovine Serum (FBS) from Hyclone Human breast cancer cell lines MDA-MB-231 
(ATCC) and Murine mammary carcinoma cell line JygMC(A) was grown in 
RPMI-11995 media purchased also from Gibco BRL (Gaithersburg, MD). All cell lines 
were grown in medium containing10% FBS, 100 units/ml penicillin, and 100 µg/ml 
streptomycin at 37°C either under normoxia (5% CO2, 21% O2) or hypoxia (5% CO2, 
0.5% O2, balanced with N2) conditions. 
 
 
Reagents and Antibodies 
 
YC-1 was purchased from AXXORA, LLC. (San Diego, CA), Benzamide, 
2-iodo-N-[1-(phenyl methyl)-1H-benzimidazol-2-yl] (G3) was purchased from Ryan 
Scientific, Inc (Mt. Pleasant, SC.), while CJ-3-60 was synthesized based on its structural 
similarity to G3 by Dr Wei Li’s lab at the University of Tennessee health Science center. 
All compounds were dissolved in dimethyl sulfoxide (DMSO) to 100 mM stock solution 
and stored at –80 °C. 
 
 
Transfection of VEGF Promoter and Screening for Anti-HIF-1α  
Compounds 
 
An expression vector pSV40-β-gal (Promega), which expresses a β−galactosidase 
(LacZ) reporter gene and enables transfected cells to become blue cells after X-gal 
staining, was used to optimize the conditions. We determined the optimal transfection 
rate in the cells in 96-well tissue culture plate by the transfection reagent Fugene 6. 
Subsequently, after determining the correct amount of DNA required, we transiently 
transfected a chimeric construct containing a 2.4-kb VEGF promoter and a luciferase 
reporter gene (pVEGF/Luc) into MDA-MB-231 cells by Fugene 6 (Roche, Indianapolis, 
IN) according to the manufacturer’s instructions.  
 
The transfection was carried out in the following way: Cells were seeded in a 96 
well plate (5x104 cells/ ml, 100µl/well). After 4-6 hr they were treated with various 
concentrations (0, 1, 10, and 100) of the respective anti HIF-1α compounds throughout 
the experiment. 48 hr after transfection, the cells in drug treatment were incubated in 
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hypoxic condition (37oC in 5% CO2, 0.5% O2) conditions for another 18 hr. The cell 
extracts were then harvested and analyzed for luciferase activity using Luciferase Assay 
Kit (Promega) according to the manufacturer’s instructions. After lysis, 2 µl of total 20 µl 
cell extracts per well was used to detect protein concentration for normalization 
(Coomassie Plus Protein Assay Reagent, Pierce), and the remaining 18µl of the cell 
extract was used to measure luciferase activity (Luciferase Assay System, Promega), and 
detected by using a 96-well plate luminometer (Synergy HT Multi-Mode Microplate 
Reader, BioTek, Winooski, VT). At least three independent experiments were done with 
each performed in triplicates. The known anti-HIF-1α agent, YC-1, was used as a 
positive control whenever new or existing candidate compounds were screened. 
 
 
ELISA 
 
Cells were plated in six-well plates and cultured to 80–90% confluence. The 
medium was replaced and cultures were treated with indicated concentrations of 
compounds, followed by incubation under normoxic or hypoxic conditions for 24 hr as 
indicated. Secreted VEGF in extracellular medium was quantified (R&D Systems, 
Minneapolis, MN) by comparison with a series of VEGF standard samples included in 
the assay kit. VEGF level in each experiment was measured twice. 
 
 
Cell Viability and Cytotoxicity Assay 
 
Cells were either treated or untreated with compounds in 96-well tissue culture 
plates (5x103 cells per well) for 72 hr. For experiments involving a six-day testing period 
in normoxia, the cells were treated with or without medium that contained test 
compounds (0, 0.1, 1, 10,100 µM respectively), which were replaced with fresh culture 
medium that contained the same test compound after three days (results not shown). 
Following the incubation period, cell viability was determined by MTT 
[3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide] kit assay as described by 
the manufacturers (Sigma). Absorbance at 570 nm was measured on a BioTek Synergy 
plate reader with background absorbance at 690 nm. 
 
 
Results 
 
 
Optimization of Transfection Efficiency in Cell Line 
 
The highest transfection rate (about 40%) was achieved in the cells in a 96-well 
tissue culture plate by transfection reagent Fugene 6 and AdRSVlacZ (which expresses 
an E.coli β-galactosidase gene, and becomes blue after X-gal staining) (Figure 2-4). 
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Figure 2-4. Cells expressing β galactosidase genes becoming blue after staining. 
Using lac z as a reporter gene in our transfection, we verified that the cells expressed 
ability to be transfected, and determined the optimal amount of DNA required for 
transfection. 
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Screening for Novel Anti-HIF-1α  Compounds 
 
HIF-1α is a transcriptional activator VEGF gene promoter [64-67]. We have in 
previous experiments used a chimeric construct, pVEGF-Luc, fused to a luciferase 
reporter gene to demonstrate and measure the functional activity of HIF-1α [68]. 
Therefore we transfected pVEGF/Luc into treated and untreated MDA-MB-231 cells, and 
measured the VEGF inhibitory effect of these drugs. This was done to (a) confirm that 
this screening system had the ability to identify a potential anti-HIF-1α compound by 
measuring the quantity of the HIF-1 inducible gene-VEGF (b) screen numerous 
compounds simultaneously with high efficiency and, (c), identify a potential (either novel 
or existing) anti-HIF-1α compound and compare the quantity of the HIF-1 inducible 
gene-VEGF with a known drug like YC-1. We observed a huge induction of 
VEGFpromoter transactivity by hypoxia in untreated cells, compared to that in drug 
treated, indicating an impressive inhibition of VEGF and the transactivator, HIF-1α by 
YC-1 (Figures 2-5). VEGF secretion in normoxia and hypoxia condition was measured to 
further confirm the effect of YC-1 on VEGF proteins secreted by cells compared to 
untreated. The result indicates that secreted VEGF proteins were reduced under normoxia 
when compared with hypoxia, and YC-1 induced an inhibition of the protein in both 
normoxia and hypoxia (Figure 2-6). An MTT assay was also done to investigate the 
cytotoxic effect of YC-1 on the cells. In the human breast tumor MDA-MB-231, YC-1 
decreased cell viability/proliferation by ~ 60% at 10 µM after 72 hr (Figure 2-7). 
 
 Of the hundreds of compounds screened from a defined small molecule library, 
we identified one compound, a structural analogue of YC-1, G3 (Figure 2-8), that 
displayed more potent anti-HIF-1α activity when compared to an established drug like 
YC-1 (Figure 2-9).The potency of G3 was further tested by MTT assay (Figure 2-10), 
and the inhibitory activity of G3 against cell proliferation was observed in the different 
breast cancers cell lines used. 
 
In search of a more potent small-molecule inhibitors of HIF-1α mediated 
transcription, we embarked on screening several small molecule compounds synthesized 
by Dr Wei Li’s lab (Department of Pharmaceutical Sciences, University of Tennessee 
Health Science Center, Memphis.TN), as analogues of G3 (Figure 2-11), with the aim to 
discover a novel compound using this screening system. These compounds were screened 
as described above using luciferase, MTT, and ELISA assays sequentially, and the most 
potent of them -a compound we named CJ-3-60- (Figure 2-12) was singled out for further 
testing (Figures 2-13, 2-14, 2-15). 
 
 The VEGF concentrations were quantified by comparison with a series of VEGF 
standard samples included in the assay kit. VEGF level in each experiment was measured 
twice. The level of VEGF protein expression was markedly lower in G3 and 
CJ-3-60-treated cell than in YC-1-treated cells (Figure 2-12). In addition, these levels 
were lower in the CJ-3-60 -treated cells than the G3 -treated cells at the same 
concentration (Figure 2-15). 
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Figure 2-5. Luciferase assay with YC-1 treated MDA-MB-231 cells. 
 
MDA-MB-231 cells were transfected with VEGF reporter that contains the 2.4 kb human 
VEGF promoter element inserted upstream of firefly luciferase vector. After transfection, 
the cells were cultured for 48 hr, while being incubated with YC-1 at different 
concentrations indicated. Cells were incubated in hypoxia for the last 18 hr. Protein 
concentrations from respective wells were used to normalize the luciferase reading. 
VEGF transcriptional activation was indicated by the relative luciferase activity in the 
cells. The data indicate that YC-1 inhibited VEGF transcriptional activation in a dose-
dependent manner. The figure shows mean ± SD of relative luciferase activities for each 
group when compared to that of the control. (* indicates p <0.05 when compared to the 
control).  
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Figure 2-6. VEGF ELISA of YC-1 treated MDA-MB-231 cells. 
 
Conditioned Media and VEGF Enzyme-Linked Immunosorbent Assay.MDA-MB-231 
cells were plated in a six-well plate at a density of 3 × 105 cells/well. Cells were treated 
with YC-1 (0, 10 and 100 µM) for 72 hr in normoxia and were then subjected to hypoxia 
for 24 hr. VEGF levels in the conditioned media were quantified by using the Quantikine 
human VEGF Immunoassay kit (R&D Systems, Minneapolis, MN) according to the 
manufacturer’s recommended protocol. The VEGF concentrations were quantified by 
comparison with a series of VEGF standard samples included in the assay kit. Data 
shown are averages from one representative experiment performed in duplicate and the 
bars indicate standard deviation. The p values are provided when there is a statistically 
significant difference. (* indicates p <0.05 when compared to the hypoxic control). 
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Figure 2-7. MTT assay of YC-1 treated MDA-MB-231 cells. 
 
Proliferation of MDA-MB-231 breast cancer cells is inhibited by YC-1 in a dose-
dependent manner. The inhibitory effect of YC-1 on the growth of MDA-MB-231 cells 
were tested using a 3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT) assay. MTT assay was determined at 570 nm and expressed as cell survival 
relative to control. MDA-MB-231 cells were treated with 0, 0.1, 1, 10, and 100 µM of the 
drug 72 hr. The values are shown as mean S.D. of triplicate wells, and experiment was 
repeated three times. * indicates p < 0.05 when compared to the control. 
 
 
 
 
 
 
Figure 2-8. Structure of benzamide, 2-iodo-N-[1-(phenyl 
methyl)-1H-benzimidazol-2-yl] (G3). 
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Figure 2-9. Throughput screening system for anti-HIF-1α compounds (YC-1 and 
G3). 
 
To identify novel compounds for HIF-1 pathway inhibition, numerous compounds from a 
library of compounds structurally analogous to YC-1 were screened. MDA-MB-231 cells 
were plated in 96 well plates and treated with serial dilution of YC-1 and G3 respectively 
in triplicates. Luciferase assay were conducted similarly to that described in the earlier 
section. Out of all the compounds screened, G3 displayed more compelling anti HIF-1 
effect when compared to YC-1. * indicates p < 0.05 when compared to the control, # 
indicates p < 0.05 when compared to YC-1 at the same concentration. 
 
 
 
 
 
 
Figure 2-10. MTT assay of YC-1 treated compared with G3 treated MDA-MB-231 
cells. 
 
Cells were treated with YC-1 or G3 as described in the materials and methods section. 
Each value is presented as mean ± S.D. of three independent experiments. These data 
indicated that G3 also inhibited cell proliferation/viability in a dose-dependent manner, 
and this inhibition is more potent in cells treated with YC-1. (* indicates p < 0.05 when 
compared to the control). 
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Figure 2-11. Sample analogues of G3 highlighting, in green box, one of the 
compounds –CJ-3-60- with the most superior anti HIF-1 performance.  
Used with permission from Dr Wei Li, Department of Pharmaceutical Sciences, 
University of Tennessee Health Science Center, Memphis. Tennessee. 
 
 
 
 
 
 
 
Figure 2-12. Structure of CJ-3-60 (C22H19N3O).  
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Figure 2-13. Luciferase assay of MDA-MB-231 cells treated with respective drugs. 
 
To identify novel compounds for HIF-1 pathway inhibition, numerous compounds from a 
library of compounds structurally analogous to YC-1 were screened. Result here shows 
that CJ-3-60 exhibited the most potent anti HIF-1 effect on the breast cancer cells when 
compared to G3 and YC-1. * indicates p < 0.05 when compared to the control; # indicates 
p < 0.05 when compared to YC-1 at the same concentration. 
 
 
 
 
 
 
Figure 2-14. Determination of MDA-MB-231 cell viability treated with YC-1, G3, 
or CJ-3-60 by MTT assay. 
 
Cells were treated with YC-1, G3, or CJ-3-60 as described earlier for 72 hr. These data 
indicated that all drugs inhibited cell proliferation/viability in a dose-dependent manner, 
and this inhibition is more potent in cells treated with CJ-3-60. * indicates p < 0.05 when 
compared to the control. 
 
      
0 1 10 100
0
500
1000
1500
2000
YC-1
G3
CJ-3-60
*
**
#
#
Concentration of Drug (µM)
Lu
ci
fe
ra
se
 a
ct
iv
ty
 (R
LU
/u
g 
pr
ot
ein
)
  
0 0.1 1 10 100
0
50
100
150
YC-1
G3
CJ-3-60
*
*
*
* *
*
*
*
*
*
* *
p<0.015
p<0.02p<0.05
Concentration (µM)
R
el
at
iv
e 
P
er
ce
nt
ag
e 
of
 C
el
l v
ia
bi
lit
y
  25 
 
 
 
Figure 2-15. Quantification of VEGF concentrations by ELISA. 
 
When compared to the untreated control, VEGF reporter activity was decreased by ~25% 
of the control in the cells treated with 10 µM YC-1, ~50% with G3, and ~80% with 
CJ-3-60. These data indicated that YC-1, G3, and CJ-3-60 inhibited VEGF transcriptional 
activation in a dose-dependent manner, and this inhibition is more potent in cells treated 
with CJ-3-60. The figure shows mean ± SD of relative luciferase activities for each group 
when compared to that of the control. * indicates p < 0.05 when compared to the 
untreated control and # indicates p < 0.05 when compared to G3 at the same 
concentration. 
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 Investigation of the effect of CJ-3-60 and G3 on cell proliferation revealed a 
strong dose-dependent inhibition in MDA-MB-231 and JygMC(A) cell lines. Compared 
with controls, and YC-1, the treatment of MDA-MB-231 and JygMC(A) cell lines with 
CJ-3-60 and G3 for 4 days under normoxia resulted in more reduction  in the total 
number of cells-with greater reduction observed in wells treated with CJ-3-60. An 
extended cell proliferation/viability study (6 days) suggests that MDA-MB-231 and 
JygMC(A) cells are more sensitive to the growth inhibitory effects of these compounds 
(data not shown). 
 
 
Conclusion 
 
 The high throughput screening system (HTSS) has the ability to identify a 
potential anti-HIF-1α compound by measuring the quantity of the HIF-1 inducible 
gene-VEGF. For initial mechanistic studies, we selected YC-1, an agent previously 
characterized as a HIF pathway inhibitor as a control. At the outset, using biochemical 
techniques, we confirmed the inhibitory activity of YC-1 on the HIF pathway by 
performing experiments with the hypoxia-responsive promoter of the endogenous HIF 
transcriptional target gene vascular endothelial growth factor (VEGF) in breast cancer 
MDA-MB-231 cell line. 
 
 Having verified that the (HTSS) could detect an anti HIF-1α compound, we 
proceeded to screen a large library of compounds with structural similarity to YC-1 in 
order to identify existing compounds that effectively inhibit VEGF signaling pathway. 
Over 400 compounds were evaluated in an MDA-MB-231 cell luciferase based reporter 
assay for HIF-1 inhibitory activities, from which we identified a compound we called G3. 
Based on the structure of G3, numerous novel compounds were synthesized and screened 
using the HTSS. One of the compounds (CJ-3-60) was selected based on its superior anti-
HIF-1 performance when compared with YC-1 and G3. There was a significant inhibition 
of VEGF and the transactivator, HIF-1α, by YC-1, G3, and CJ-3-60. Compared with 
YC-1, G3 exhibited a more dramatic inhibition of HIF-1α than YC-1, and CJ-3-60 
exhibited the most (compared to both) in all concentration. 
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CHAPTER 3.    NOVEL THERAPEUTIC COMPOUND INHIBITS HIF-1 α 
BREAST CANCER CELL GROWTH IN VITRO   
 
 
Introduction 
 
Several investigations have reported increase levels of HIF-1α expression in 
proliferating and/or growth factor-stimulated cells [36]. HIF-1 plays a crucial role in the 
establishment and progression of common human cancers by activating the transcription 
of genes encoding proteins that mediate metabolic adaptation, like glucose transporters 
and glycolytic enzymes, angiogenesis (VEGF), and cell survival (IGF-2). These regulated 
gene products facilitates in the invasion and metastasis of the cancer cells. Also an 
increase in HIF-1α expression possibly contributes extensively to the development of the 
deadly cancer phenotype. The link between alterations of major signal-transduction 
pathways and of HIF-1α expression highlights the fundamental role of HIF-1 in cancer 
biology. Increased levels of HIF-1α have been linked with increase proliferation and are 
potentially associated with more aggressive tumors [69]. 
 
Apoptosis, or programmed cell death, is a tightly regulated endogenous process 
that requires a coordinated activation of signaling pathways. It is regulated by balance of 
pro and anti-apoptotic proteins; mediated by the caspase proteins. Cellular apoptosis 
often occurs when cells are exposed to extreme hypoxia, and the adaptive mechanism 
initiated by HIF-1 that offers some protection is not sufficient, as reviewed in Piret, et al. 
[70]. One mechanism that has been suggested by which HIF-1 may induce apoptosis is 
that hypoxia induces the stabilization of p53 protein, a potent nuclear transcription factor 
that can trigger a wide array of target genes that initiate cell death in response to stress or 
DNA damage [71]. The stabilization of p53 in hypoxia corresponds to the increase of 
HIF-1α in the cells, and co-immunoprecipitation experiments suggest a direct association 
between p53 and HIF-1α in hypoxia cells [72, 73]. This direct interaction between p53 
and HIF-1α results in both the stabilization of p53 and an inhibition of HIF-1 dependent 
transcription. Competitions between p53 and the co activator p300 for the same 
transactivation domain HIF-1α may in part explain this effect [74, 75]. 
  
Conversely, in several experimental conditions, hypoxia has also been reported to 
repress apoptosis. This effect is preliminarily evidenced at the hypoxia level that leads to 
the activation of HIF-1α through the dimerization of HIF-1α and HIF-1β, and adaptive 
increase in the transcription of genes associated with adaptation and ultimate survival. 
This anti-apoptotic role of HIF-1 may in part explain why breast tumors (and indeed all 
tumors) with a high HIF-1 expression are often resistant to chemo and radiation therapy 
[76]. In breast carcinoma there is a strong positive correlation between tumors expressing 
both HIF-1 and Bcl-2 (the anti-apoptotic protein) and a worse prognosis [77]. Also, 
Pidgeon, et al. has demonstrated that VEGF up-regulates Bcl-2 and down-regulates 
tumor cell apoptosis in human and mammary adenocarcinoma cells [78]. This seemingly 
conflicting actions of HIF-1α was summarized by the research conducted by Suzuki, et 
al. when they suggested that two distinguishable forms of HIF-1α were responsible these 
contrasting activities: posphorylated HIF-1α dimerizes with HIF-1β while 
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dephophorylated HIF-1α links with p53, stabilizes p53 and induces apoptosis through 
Bax overexpression [79]. 
Materials and Methods 
Western Blot 
Expression or and inhibition of HIF-1α and HIF-1β was analyzed by 
immunoblotting using a monoclonal mouse anti-HIF-1α and monoclonal rabbit 
anti-HIF-1β antibody respectively. Corresponding secondary anti body was used and a 
mouse anti-β-actin antibody was used for normalization. Cells were treated with 0, 1, 10, 
and 100 µM of YC-1, G3, and CJ-3-60 respectively 72 hr before being cultured for the 
last 18 hr under hypoxic (H, 0.5% O2 v/v) conditions. G3 and YC-1 served as controls 
throughout the experiments. 
Cells were lysed in lysis buffer containing 10mM Tris-HCl (pH 8.0), 0.25 M 
Sucrose, 0.05 mM CaCl2, 0.02% Azide, 0.5% NP-40, 1x protease inhibitor cocktail 
(Sigma,St. Louis, MO), and 1x phosphatase inhibitor cocktail I and II (Sigma), and 
processed for gel electrophoresis. Protein concentration was determined by using 
Coomassie Plus Protein Assay Reagent (Pierce,Rockford, IL). Protein extracts were 
loaded on a precast 4-12% gradient polyacrylamide gel (NuPAGE gel, Invitrogen, 
Carlsbad, CA) (100 µg/per lane) and subject to SDS-gel electrophoresis, followed by 
transferring to a polyvinylidene fluoride (PVDF) membrane (Immobilon-P Transfer 
Membrane, Millipore).  
The membrane was incubated with blocking solution (5% nonfat milk and 0.02% 
sodium azide in phosphate-buffered saline) overnight at 4oC, followed by an incubation 
for 16 hr at 4oC with these respective antibodies: mouse anti-human HIF-1α antibody 
(1:1,000 dilution, cat # 61958, BD Biosciences); Anti HIF-1β, 1:1000, cat # H0306 Santa 
Cruz Biotechnology); Anti-Bcl–2 1:1000 dilution, cat #2876, Cells Signaling). The 
membrane were then incubated for 1 hr at room temperature with corresponding 
secondary antibody coupled to peroxidase, followed by detection with chemiluminescent 
reagents (ECL kit, Amersham). The blots were quantified using ImageJ (NIH) and the 
density of the band compared.  
Flow Cytometry 
To measure drug-induced apoptosis, annexin- V- phycoerythrin (PE) and SYTOX 
double assay was performed using the Annexin V-PE Apoptosis Detection Kit Plus 
(Medical &Biological Laboratories) according to the manufacturer’s instructions. Briefly 
MDA-MB-231 cells were cultured in 6-well plates at a density of 3 × 105 per well and 
untreated or treated with different concentrations of YC-1, G3, or CJ-3-60 (0, 0.1, 1, 10 
µM) for 72 hr at 37°C. Results were calculated as the mean fluorescence intensity and 
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expressed as the fold difference from the untreated and control group treated with vehicle 
alone (0.04% DMSO). The cells were trypsinized and washed with PBS. The washed 
cells were resuspended in 500-µL binding buffer and stained with 5 µl of Annexin V-PE 
and 1 µl of SYTOX and allowed to incubate at room temperature for 5-10 min in the 
dark. Flow cytometric analysis was performed immediately after. Experiments were 
conducted in duplicates and were independently repeated twice. 
 
 
Caspase-Glo 3/7® Assay 
 
The induction of Apoptosis was investigated by measuring the levels of caspase 
3/7 using caspase-Glo 3/7® assay (Promega). Briefly, 0.1, 1, 10, and 100 µM of drug was 
added to final volume 100 µl of media in each well. Three different plates with duplicates 
of each concentration being investigated were incubated for 24, 48, and 72 hr 
respectively in hypoxia or normoxia. Following the incubation period, the plates were 
processed for caspase-3 activity as described by the manufacturers. The fluorescence 
intensity –a reflection of the caspase-3/7 activity- was measured by a 96-well plate 
luminometer (Synergy HT Multi-Mode Microplate Reader, BioTek, Winooski, VT). 
After subtracting the background reading, caspase-3 activity was expressed as a 
percentage increase compared to untreated control cells.  
 
 
Results 
 
 
Effects of Compounds on Hypoxia-Mediated HIF-1α  Expression 
 
CJ-3-60 inhibits hypoxia-induced HIF-1α secretion more effectively than YC-1 
and G3.We analyzed the effect of YC-1, G3, and CJ-3-60 on hypoxic induction of 
nuclear HIF-1α protein in MDA-MB-231 and JygMC(A) cells by 
immunoblotting.  MDA-MB-231 were cultured and treated in the absence or presence of 
YC-1, G3, and CJ-3-60 (0, 1, 10, and100 µM) as described earlier. CJ-3-60 specifically 
inhibited HIF-1α protein accumulation under hypoxia in a dose dependent manner in 
these cell lines, and more effectively than YC-1, G3, and CJ-3-60 (Figure 3-1a-d). 
However, it was found to have no effect on the protein levels of HIF-1β (Figure 3-2). 
 
More than 75% (in MDA-MB-231 cells) and 50% (in JygMC(A) cells) protein 
reduction was observed between the compound treated samples and the control of the 
HIF-1α at concentrations that inhibit HIF-1α activation. CJ-3-60 and G3 inhibited 
hypoxia (0.5% O2)-induced HIF-1α activation by ~95% at the concentration of 1 µM 
compared to ~70 for G3 and YC-1 in both cell lines (Figure 3-1c-d). 
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Figure 3-1. Western blot analysis of HIF-1α proteins in nuclear extract samples 
prepared from MDA-MB-231 and JygMC(A) cells. 
 
Expression of HIF-1α and actin proteins was analyzed by immunoblotting with a mouse 
anti-HIF-1α, mouse anti-actin antibody, respectively. CJ-3-60 specifically inhibited HIF-
1α protein accumulation under hypoxia in a dose dependent manner in these cell lines, 
and more effectively than YC-1 and G3 in MDA-MB-231 cells (a) and JygMC(A) cells 
(c).Quantified graphs(b and d). Data represent means±S.D. from three independent 
readings (* indicates p < 0.05 when compared to the control). 
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Figure 3-2. Western blot analysis of HIF-1β proteins in nuclear extract samples 
prepared from MDA-MB-231. 
 
Levels of HIF-1β protein was not significantly affected in the presence of compounds (a). 
Quantification of HIF-1β western blot normalized with expression levels of actin (b). 
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Exposure to Compounds Induced Apoptosis in Cells 
 
Flow cytometry with Annexin V-FITC/PI staining showed that the drug treatment 
significantly increased the proportion of apoptotic cells. Based on staining the cells with 
Annexin V- PE, flow cytometry was used to quantify the degree of apoptosis (Figure 
3-3a-c).The point of lower left quadrant (Q3) in Figure 3-3a represents the life cells with 
few early apoptotic cells, the point of upper right quadrant (Q2) represents the late 
apoptotic cells, the point of lower right quadrant (Q4) represents the necrotic cells. Figure 
3-3b shows the result from all samples, untreated and treated (0-10µM) of YC-1, G3 and 
CJ-3-60. 
 
As demonstrated in Figure 3-3c, the maximal apoptosis rate was ~60%, observed 
in cells treated with 10 µM of CJ-3-60, which was significantly higher than the other 
group’s lower or equal concentrations. In the vehicle treated cells, 2% were positive for 
Annexin. Drug treatment resulted in 20%, 30%, and 40% in apoptosis when cells were 
treated with 1 µM YC-1, G3 and CJ-3-60, respectively. This result confirms the ability of 
all compounds to induce apoptosis in MDA-MB-231 cells, with the highest percentage 
seen in cell treated with CJ-3-60 at same concentration. 
 
CJ-3-60 and G3 increases the levels of caspases 3/7. Studies have reported that 
inhibition of cell proliferation by YC-1 in some cancer cell line might be mediated by 
apoptosis [80, 81]. Therefore we examined the apoptosis-inducing capacity of CJ-3-60 
and G3 by measuring the activation of caspases 3 and 7. The plating of cells, compound 
treatment, and exposure to normoxic and hypoxic conditions were similar to those 
described in the earlier sections. In these cells, the level of caspases 3 and 7 increased up 
to within 72 hr in response to increasing concentration of drug, compared with the 
untreated control. We found a direct correlation between impaired cell growth and 
apoptosis: activation of apoptosis by CJ-3-60 and G3 in these experiments was evident 
only after 48 hr of treatment (Figure 3-4a and b). A dose-dependent increase in active 
caspase-3/7 in YC-1, G3, and CJ-3-60-treated cultures was observed in all time period, 
and CJ-3-60 significantly induced the highest levels of caspase 3/7 at the end of 72 hr. 
Similar trend was observed in cells cultured in normoxia (results not shown). 
 
CJ-3-60 and G3 also inhibits levels of anti- apoptotic Bcl-2 in these cell lines 
more effectively than YC-1.To determine whether YC-1, G3, and CJ-3-60 
apoptosis-inducing activity is through the Bcl-2 pathway, we investigated the level of 
Bcl-2 protein in MDA-MB-231 and JygMC(A) cell lines by western blot analysis as 
described above, with 100µg of extracted protein from LNCaP-Bcl-2 cells (a generous 
gift from Dr Leonard Lothstein, University of Tennessee Health Science Center) serving 
as a positive control. YC-1, G3, and CJ-3-60 inhibit the accumulation of Bcl-2 protein in 
a dose-dependent fashion (Figure 3-5a-c). These results demonstrate that YC-1, G3, and 
CJ-3-60 exert an inhibition of hypoxic- induced accumulation of Bcl-2 protein, which 
was measured after 72 hr of drug treatment and 18 hr in hypoxia. 
 
The changes in the expression of caspase-3/7 and Bcl-2 after YC-1, G3, and 
CJ-3-60 treatment suggests that apoptosis induced by YC-1, G3, and CJ-3-60 might be 
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Figure 3-3. Flow cytometric analysis of apoptosis. 
 
MDA-MB-231cells were incubated with YC-1, G3, or CJ-3-60 at the indicated 
concentrations for 72 hr. (a) Each sample was stained by Annexin V/PE and analyzed by 
flow cytometry. Figure 3-3a (left panel) shows the total events in untreated sample after 
the event count was gated, and cell viability was determined using a fixable green 
reagent. Data in red, broken line box (right panel) shows the statistical percentages of the 
respective events in the population. Untreated samples exhibited ~ 5% apoptotic cells 
(indicated) and more than 80% viable cells after processing. (b) Figure shown are a 
representative of three independent experiments of all samples, and the relative 
percentage of apoptosis rates of all samples (treated, untreated, and vehicle control) 
groups are shown in the bar chart (c). Higher percentage of apoptosis cells were detected 
by Annexin V-FITC and PI staining in CJ-3-60 treated cells than in other groups. 
* indicates P < 0.05 when compared to vehicle control group.  
 34
    
 
Untreated Sample
a
Untreated Untreated + DMSO
YC-1 (0.1um)
G3(1um)
YC-1 (1um)
G3 (10um)
YC-1 (10um)
G3 (0.1um)
CJ-3-60 (0.1um) CJ-3-60 (1um) CJ-3-60(10um)
b
U (U + DMSO) 0.1 1 10
0
20
40
60
Untreated
+ DMSO 
YC-1
G3
CJ-3-60*
*
*
*
*
*
*
*
*
p<0.001
p<0.001
p<0.0005
p<0.005
Concentration(µM)
R
el
at
iv
e%
 o
f A
po
pt
os
is
c
  35 
 
 
 
Figure 3-4. Total caspase 3/7 after 72 hr drug treated cells. 
 
Caspase 3/7 activity was assessed at 24 hr, 48 hr and 72 hr in triplicate wells using MDA-
MB-231 cells (a) and JygMC(A) cells (b). In this study, caspase-3/7 activities were both 
increased in a concentration-dependent and time-dependent fashion after treatment. As 
shown in Figure 3-4a and b, compounds strongly induced the activation of caspase-3/7, 
and the maximum activity was about 2-8-fold of control at the highest concentration (100 
µM), with cells treated with CJ-3-60 instigating the greatest increase (* indicates p < 0.05 
when compared to the control, # indicates p < 0.05 when compared to G3 at the same 
concentration). 
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Figure 3-5. Effects of YC-1, G3, and CJ-3-60 on Bcl-2 in MDA-MB-231 and 
JygMC(A) cells. 
 
Cells were treated with 0, 1, 10, and 100 µM YC-1, G3, and CJ-3-60 for 72 hr under 
normoxia and then 18 hr under hypoxia. Cells were then harvested and subjected to 
western Blot. Protein extracts from LNCaP/Bcl-2 cells served as positive control in lane 
one for both western blot assays. Decreased levels of Bcl-2 were detected in both cell 
lines, and the most inhibition was observed in cell treated with CJ-3-60. (a and c) 
Western blots were subsequently quantified by scanning densitometry of Bcl-2 
expression and normalized to that of β-actin (b and d). The means indicated with an 
asterisk were statistically different from the matched hypoxic control. * indicates p<0.05. 
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one of the mechanisms by which these compounds acts as an anti-proliferative drug 
against these cancer cells. 
 
 
Conclusion 
 
Hypoxia greatly increases the protein level of HIF-1α, but these compounds 
inhibited the hypoxic accumulation of HIF-1α in a dose dependent manner. The effect of 
YC-1, G3, and CJ-3-60 on HIF-1α level was also examined in MDA-MB-231 and 
JygMC(A) cells to verify that YC-1, and examine the possibility that G3 and CJ-3-60 
affects HIF-1α protein under hypoxic conditions. The result confirms that YC-1, and 
reveals that G3, and CJ-3-60 has an effect on HIF-1α accumulation. In contrast, the 
density of HIF-1β protein band was unaltered by drug treatment, which suggests that the 
YC-1, G3, and CJ-3-60 effect is specific to HIF-1α.  
 
One of the most described pathways for cell death involves the activation of 
caspase 3 or 7 [82]. Here we report that YC-1, G3, and CJ-3-60 directly induce cell death 
in breast cancer cells through caspases 3 and 7. Several cellular steps are required to 
activate apoptosis. Among these steps, the Bcl-2 accumulation in cells is considered to be 
a key step in the induction of apoptosis; therefore we further characterized apoptosis 
triggered by YC-1, G3, and CJ-3-60 by examining levels of Bcl-2 protein. The results 
demonstrate that YC-1, G3, and CJ-3-60 exerts a dose-dependent inhibition of 
hypoxic-induced accumulation of Bcl-2 protein, which is manifested after 72 hr of drug 
treatment and 18 hr in hypoxia, leading to caspase-mediated cell death.  
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CHAPTER 4.    NOVEL THERAPEUTIC COMPOUND INHIBITS TUMOR 
CELL-INDUCED ANGIOGENESIS 
 
 
Introduction 
 
Numerous investigations have shown that primary tumors are incapable of 
growing beyond a volume of several mm3 in the absence of new vascularization meant to 
provide a fresh supply of oxygen, glucose and other nutrients [83, 84]. The inception of 
angiogenesis (and eventual vascularization of the tumor) allows the accelerated growth of 
the tumor, subsequently preparing the environment for the development of the invasive 
and metastatic properties that characterize the deadly cancer phenotype. Concurrently, as 
observed in many tumor types, there is a statistically significant correlation between 
tumor angiogenesis and patient survival [85]. 
 
 Tumor angiogenesis occurs as a result of a tilt in balance between angiogenic and 
antiangiogenic factors. The most prominent angiogenic factor revealed to play a critical 
role in mediating blood vessel formation in response to developmental, physiological, or 
oncogenic stimuli, is vascular endothelial growth factor (VEGF) [15, 46, 47, 83, 84]. A 
strong parallel has been described between VEGF expression and clinical outcome in 
numerous types of tumor [86]. Whenever VEGF expression is inhibited or a binding of 
its receptor on endothelial cells occurs, a remarkable effect on tumor growth, invasion, 
and metastasis in animal models has been observed [65, 87-94]. HIF-1, in response to 
hypoxia, plays a prominent role in coordinating the transcription of a host of genes in the 
tumor cells, one of these being VEGF. The production of VEGF sequentially initiates and 
sustains new blood vessel development, essential for cellular proliferation and tumor 
development [95-99].  
 
 Furthermore, HIF-1 activates other pro-angiogenic agents like thymidine 
phosphorylase, and targets the gene encoding inducible nitric oxide synthase (iNOS), 
which plays a role in tumor vascularization. It has additionally been shown in animal 
xenograft studies that HIF-1/HIF-1α enhances tumor growth and angiogenesis [52, 83, 
84, 100]. VEGF expression is not only induced by hypoxia, but also by exposure of both 
transformed and non-transformed cells to a variety of growth factors, like epidermal 
growth factor, basic fibroblast growth factor (FGF-2), insulin-like growth factor 
1(IGF-1), interleukin 1β, platelet-derived growth factor, and tumor necrosis factor α 
(TNF- α) [101-105]. Interestingly, these growth factors also induce HIF-1α protein 
expression and/or HIF-1 DNA binding activity [106-109]. HIF-1α overexpression in 
tumor biopsies is linked with vascular density in ductal carcinoma in situ (the early pre 
invasive stage of breast cancer) [110], further substantiating that HIF-1 activity 
contributes to the angiogenic switch.  
 
Based on these and other numerous observed upregulation of HIF in cancer, and 
its role in upregulating angiogenic growth factors (which ultimately increases tumor 
growth), one could hypothesize that an inhibition of the HIF pathway would reduce both 
angiogenesis and tumor growth. This has also been confirmed by a study using peptides 
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that block the interaction between the HIF-1α carboxyl terminus and the transcriptional 
co-activator p300, which reportedly leads to a reduction in growth and angiogenesis in 
tumors derived from breast and colon carcinoma cells [111].  
 
 
Materials and Methods 
 
 
Western Blot Analysis of VEGF Proteins 
  
 The protein levels of VEGF were analyzed in whole cell lysates by western blot 
analysis as described in previous sections of this report, using a monoclonal rabbit anti-
human antibody against VEGF, and the protein concentration of each lane was 
normalized by β-actin.  
 
 
In vitro  Network Formation Assay  
 
To determine whether potential therapeutic compound(s) inhibit tumor 
cell-induced angiogenesis, culture supernatants from MDA-MB-231 cells treated either 
with or without drug (1-100 µM) under hypoxia or normoxia were used as conditioned 
medium for the network formation assay. 200µl ice-cold matrigel (BD Bioscience) was 
added to coat each well of pre-chilled 48-well plate, and then incubated for 1 hr at 37°C 
to become polymerized. Human microvascular endothelial cells (HMEC) (3 × 104 
cells/well) were seeded with 300µl of culture supernatants from above. The network-like 
structure of the cells was photographed at 0, 2, 5, 8, 11, and 24 hr post HMEC plating on 
the matrigel. Five randomly selected fields at 5, 8,and 11 hr were counted for the vessel 
crossing points in order to compare network connections (i.e. network formation) in a 
quantitative manner, and represented as mean + SD.  
 
 
Result 
 
 
Compounds Inhibit the Induction of VEGF Proteins in MDA-MB-231 
Cell Line and Stimulation of Network Formation 
 
Given that HIF-1 is the main regulator of VEGF expression in hypoxia we 
analyzed the effect of these compounds on VEGF production in vitro, measured with an 
enzyme-linked immunosorbent assay (ELISA) (Figure 4-1). We showed by western blot 
(Figure 4-1b) that CJ-3-60 at 10 µM almost completely blocked the hypoxic induction of 
secreted VEGF proteins (p < 0.05), when compared with the control, while G3 inhibited 
hypoxic induction of cellular and secreted VEGF proteins at the concentration of 100 
µM.  
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Figure 4-1. Compounds inhibit the induction of VEGF proteins in vitro. 
 
Drugs inhibit VEGF expression in MDA-MB-231 cells. The protein levels of VEGF were 
analyzed in whole cell lysates by western blot analysis using a monoclonal rabbit 
anti-human VEGF antibody and the protein concentration of each lane was normalized by 
β-actin. (b) Quantified graphs based on densitometric analysis of ratio between VEGF 
and actin protein expression. The figure shows mean ± SD of relative VEGF expression 
for each group. * indicates p<0.05 when compared to the control. 
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Compounds Inhibit the Stimulation of Network Formation 
 
A human microvascular endothelial cells (HMEC)-based in vitro angiogenesis 
assay was employed for further study to explore if the inhibition of VEGF protein 
production would parallel the inhibition of tumor angiogenesis. One common method 
used to quantify the degree of angiogenesis in the HMEC network formation assay is by 
counting the number of branching points formed by the networks. In the absence of 
required angiogenic factor, HMECs failed to form much significant network throughout 
the plate observed at eight hours after incubation (Figure 4-2a, Basal Media). However, 
the addition of the angiogenic factor (VEGF, 15ng/ml) stimulated the HMECs to form 
network-like structures (Figure 4-2a, Basal Media + VEGF, 15ng/ml).  
 
Similar angiogenesis inducing activity was detected in HMECs cultured with 
conditioned media from hypoxic MDA-MB-231 cells at similar time point, which 
displayed a drastically enhanced angiogenesis stimulating activity (Figure 4-2b, Control 
Hypoxia) when compared to conditioned media collected from MDA-MB-231 cells 
cultured under normoxic conditions (Figure 4-2b, Control Normoxia).Invariably, we can 
reasonably conclude that hypoxia enhances the production of angiogenic factors (likely 
VEGF), essential for the formation of network. Both CJ-3-60 and G3 suppressed hypoxic 
MDA-MB-231 cell-induced angiogenesis at concentrations as low as 1 µM (Figure 4-2b, 
bottom bar graph), more significantly than YC-1, and less than that observed with 
untreated normoxic cells (Figure 4-2b, top bar graph). When the normoxia plus CJ-3-60 
treatment was compared with the normoxia untreated control, CJ-3-60 completely 
blocked the hypoxic induction of secreted VEGF proteins.  
 
In summary, of the three compounds assayed, CJ-3-60 demonstrated the greatest 
inhibition of the ability of hypoxic MDA-MB-231 cells to stimulate tumor angiogenesis 
in all condition and same time point (Figure 4-2b). These results compare concomitantly 
with the inhibitory actions exerted by the compounds on hypoxic induction of secreted 
VEGF proteins in MDA-MB-231 (Figure 4-1 a and b; Figure 2-15). In some related 
experiments performed separately, the angiogenesis activity was investigated in the 
presence of compound- treated HMECs with15ng/ml(Figure 4-2d) VEGF or condition 
cells cultured with the condition media used above with supplemented with 15ng/ml 
VEGF. Significant network formation was observe (that thrived as well as that observed 
in the hypoxia control), indicating that the compounds do not act directly on HMECs to 
inhibit network formation in presence of VEGF (Figure 4-2d). Lastly, a cytotoxic assay 
conducted revealed that the compounds do not have a significant cytotoxic effect on 
HMECs (Figure 4-2e). 
 
 
Conclusion 
 
 In fast growing tumors, local hypoxic conditions stimulate the expression of 
HIF-1α, which in turn induces the expression of VEGF in tumor cells. As a survival 
mechanism employed by these hypoxic tumor cells, the production of angiogenic factors 
such as VEGF is increased, which serves as a trigger to initiate the process of tumor  
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Figure 4-2. Compounds inhibit the induction of VEGF proteins and tumor 
angiogenesis in vitro. 
 
Secreted VEGF protein in the conditioned media from MDA-MB-231 cells exposed to 
various concentration of drug -0, 1, 10, 100 µM for 72 hr (in normoxia for 48 hr and in 
hypoxia or 24 hr), were evaluated in a HMEC network formation assay. Representative 
pictures are shown and the negative (Basal Media) and positive (VEGF) controls are 
shown in two different panels. The extent of network formation in four fields selected 
randomly was quantified for condition from 10 µM (a) and all concentrations for all 
compounds in normoxia and hypoxia (b), condition media enhanced with VEGF (c), and 
MTT assay done to examine cytotoxic effect of drugs on HMECs (d). The data shown are 
averages and the bars represent standard number of branching point. The p values are 
provided where there is a statistically significant difference. * p <0.05 between the 
hypoxic control and the compound treated samples, between the negative and positive 
control, or between samples cultured in conditioned media with and withoiut VEGF.  
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Figure 4-2.  Continued. 
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angiogenesis by binding to and activating the receptor on the surface of endothelial cells, 
leading to endothelial cell proliferation, migration, invasion, and eventually capillary tube 
formation.  
 
It is essential to inhibit the expression of HIF-1α and, subsequently, VEGF in 
these cells to repress the formation of new blood vessel in these tumors. Novel 
compound, CJ-3-60, was shown to inhibit hypoxic induction of secreted levels of VEGF 
protein in MDA-MB-231 cells, and we further reported the anti-angiogenic activity of 
compounds in HMECs cultured in media from 72 hr drug-treated cells that were cultured 
for the last 24 hr in hypoxia. Compounds decreased the secreted level of VEGF protein 
under hypoxia and normoxia conditions, which resulted in the disruption of in vitro 
capillary network formation in HMECs compared to untreated hypoxia control. Overall, 
this finding demonstrates that compounds hinder angiogenesis in hypoxic MDA-MB-231 
breast cancer cells by inhibiting HIF-1α accumulation. 
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CHAPTER 5.    NOVEL THERAPEUTIC COMPOUND SUPPRESSES BREAST 
TUMOR METASTASIS 
 
 
Introduction 
 
Two of the major biological characteristics of cancer cells are their unusual 
growth and metastasis, which combined is the major cause of morbidity and mortality in 
several patients with the disease [112]. Metastasis occurs in approximately half of the 
cases with apparently localized breast cancer, and death occurs in majority of the cases 
from the spreading of these cancer cells and their ultimate proliferation at secondary sites 
[113]. There are strong evidences that hypoxia represents a physiological stimulus for 
tumor cell invasion and metastasis and HIF-1 has been proven to regulate several stages 
throughout the complex metastatic process in many clinical and animal studies [36, 
114-116]. Furthermore, based on immunohistochemical analyses, reasonable levels of 
HIF-1α protein have been detected in benign tumors, high levels in primary malignant 
tumors, and a remarkable high amount in metastatic tumor, in sharp contrast to its 
absence in normal tissues [36, 117]. Likewise, angiogenesis has been widely implicated 
as critical to tumor growth, survival, and metastasis [118], a fact long established [46].  
 
 Since metastasis is one of the most critical factors associated with cancer 
therapeutic efficacy and prognostic survival, great effort is therefore warranted in 
development of new anticancer agents based on HIF-1α inhibitors. Consequently, we 
sought out to investigate effect of these compounds on the migratory activity of these 
breast cancer cells (as a reasonably good predictor of in vivo metastatic activity) through 
Cell-Based Wound Healing assay and Soft Agar Colony Formation Assay. 
 
 
Materials and Methods 
 
 
Cell-Based Wound Healing 
 
MDA-MB-231 or JygMC(A) cell lines were plated at the density of 8x106 
cells/well into 12-well plates (Corning). After 24 hr, the cells were treated with each 
specific test compound (0, 1, 10, and 100 µM of YC-1, G3, or CJ-3-60 respectively). The 
cells were washed twice with phosphate-buffered saline (PBS) solution after 24 hr of 
drug treatment, followed by a short incubation (1 hr at 37°C) with 7-5 µg/ml of 
Mitomycin C, a DNA intercalating agent known to inhibit cell proliferation (but allow 
migration), to MDA-MB-231 and JygMC(A) cell. A parallel wound was created inside 
each well by scratching the monolayer of confluent cells with a 200 µL pipette tip at a 
90° angle. Each well with freshly made wound was then washed several times with PBS 
to remove cell debris, and then re-treated with their respective corresponding 
concentration of drug to investigate its effect on the cells migration during wound healing 
under both normoxic (95% air) and hypoxic (0.5% O2) conditions. Cell migration into the 
wound surface was determined by the average distance of migrating cells under an 
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inverted microscopy at various times. Serial images of selected fields were acquired 
every 24 hr by a cell imaging workstation (Olympus CK2 Japan), coupled to a bright-
field microscope at 40x. The scratched area was measured using the Scope photo 3.0 
software and the width was calculated as a difference between the width of the wound at 
0 hr and each subsequent time period for each drug and concentration.  
 
 
Soft Agar Colony Formation Assay 
 
To test for contact-independent growth in soft agar, a 24-well Petri dish was first 
coated with 375µl base agrose consisting of 0.8 % agrose in the culture medium RPMI 
1640(MDA-MB-231 cells); DMEM 11995(JygMC(A) cells). Cells were counted, and 
resuspended at a density of 100 cells/125µl (JygMC(A) cells; 500 cells/125µl 
(MDA-MB-231 cells) in 0.4% agrose mixed in culture medium (treated and untreated). 
After introducing the mixture of cells, agrose with respective concentration of drug- 
treated media (or untreated) into the respective 24 well plate containing the base agrose, 
the immobilized cells were grown and fed with growth media (100µl/well) twice for 13 
days in a humidified chamber at 37 0C with 21% O2, 5% CO2. Plates were then stained 
with 0.05% crystal violet in PBS for 1 hr, and the colonies photographed and counted. 
The experiments were performed in duplicate, twice.  
 
 
Results 
 
 
Compounds Inhibit in vitro  Migration of MDA-MB-231 and JygMC(A) 
Cell Lines under Both Normoxia and Hypoxia Conditions 
 
Having shown that these compounds inhibited hypoxia-induced HIF-1 activation 
in these cell lines, we then studied their effects on MDA-MB-231 and JygMC(A) cell 
migration in a wound-healing assay as an in vitro model for this study as described under 
the materials and methods. Over a 72 hr period, MDA-MB-231 cells migrated into the 
wounded area and resulted in closure of the wound (Figure 5-1a-d). All compounds at 
100 µM suppressed MDA-MB-231 cell migration under both normoxic and hypoxic 
conditions after 72 hr (results not shown). YC-1 only modestly inhibited MDA-MB-231 
cell migration at a concentration of 10 µM, while G3 and CJ-3-60 potently inhibited the 
cell migration of MDA-MB-231 cells at10 µM after 24, 48, and 72 hr (Figure 5-1a-d); 
and also in JygMC(A) (results not shown). Meanwhile, CJ-3-60 more potently inhibited 
cell migration more significantly than G3. 
 
 In conclusion, while the untreated cells migrated and closed the wound in 
approximately 48 hr, cells treated with YC-1, G3 and CJ-3-60 did not. YC-1, though 
presenting delay versus the control, showed a lesser effect on wound-healing time than 
the other two inhibitors tested at the same concentration and duration. CJ-3-60 produced 
the most significant inhibition in both cell lines compared to the two other compounds. 
However, while the reduction was approximately half that of the control, the reduction in  
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Figure 5-1. Cell migration capability was determined with a wound healing assay. 
 
A confluent monolayer of MDA-MB-231 cells or JygMC(A) cells after a 24 hr exposure 
to different concentrations of drug or blank control was wounded. Cells were then 
incubated for 72 hr in hypoxia. Photographs were taken immediately (0 hr) and at 24 hr, 
48 hr, and 72 hr after wounding (a). The data (b-d) represent the cell migration to the 
wound areadetermined by the mean width (as a percentage compared to initial width at 0 
hr) at stated time point (24, 48, and 72 hr respectively) after wounding in two 
independent wound sites per group. * indicates p < 0.05 when compared to the control. 
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normoxia was only moderate or very slight compared to hypoxia for all cell lines and all 
drugs (Figure not shown). This lessening of wound-healing capability (or migration) of 
cells treated with G3 and CJ-3-60 is demonstrated as a near inhibition in the narrowing of 
the width of the wound compared to when they were observe at 0 hr, and an 
approximately 20-80% wider than that of the control in the treated cell lines. 
 
 
CJ-3-60 and G3 Significantly Blocked Colony Formation 
  
To determine whether YC-1, G3, and CJ-3-60 inhibited anchorage-independent 
colony formation, we cultured the cells either in the absence or presence of YC-1, G3, 
and CJ-3-60 for 13 days. The cells were incubated in a soft agar culture system, and 
colony formation was counted 13 days later. The results show a significant decrease in 
colony formation in drug-treated culture compared with untreated (Figure 5-2a-j). This 
data demonstrate that YC-1, G3, and CJ-3-60 decreased in vitro colony formation by 
MDA-MB-231 and JygMC(A) breast cancer cells in a dose dependent manner (0.1 to 10 
µM) in all assays, and that CJ-3-60 had a more potent effect on inhibiting cell colony 
formation than YC-1 and G3. 
 
 
Conclusion 
 
In the current study we reported that G3, and CJ-3-60 blocked migration of 
MDA-MB-231 and JygMC(A) cells. Cell migration plays a key role in both normal 
physiological and pathological conditions. Wound healing assay was used in 
investigating cell migration, and the inhibition exerted by YC-1, G3, and CJ-3-60 was 
determined. Although the mechanism by which hypoxia amplifies the metastatic potential 
is still being studied, it is suggested that HIF-1 drives expression of a set of downstream 
genes that control processes implicated in migration and invasion [115, 116]. 
 
Finally, we determined whether YC-1, G3, and CJ-3-60 inhibited 
anchorage-independent colony formation. Anchorage independent growth is one of the 
characteristics of tumor-cell transformation, and is regarded as one of the most precise 
and stringent in vitro assay for identifying malignant transformation of cells. It has been 
revealed that tumor cells that can form colonies in the anchorage-independent growth 
assay will be tumorogenic in vivo [52]. Therefore, since YC-1, G3, and CJ-3-60 inhibited 
colony formation (in vitro tumorigenesis) of MDA-MB-231 and JygMC(A) cells in a 
dose-dependent manner, it indicates that these compounds will likely inhibit the cell 
incursion of these breast cancer cell lines. More importantly, the soft agar colony 
formation assay demonstrated that G3 and CJ-3-60 almost completely blocked colony 
formation, in contrast, YC-1 showed less significant effect on the cells. 
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Figure 5-2. Effects of YC-1, G3, and CJ-3-60 on soft agar colony formation. 
 
(a) Colony formation in MDA-MB- 231 cells and (e) JygMC(A) cells treated with YC-1, 
G3, and CJ-3-60 compounds. The number of colonies >0.2, >0.5, and >1.0mm was 
counted and data shown are the mean values from three separate experiments for each 
group (b-e for MDA-MB-231 and g-j for JygMC(A) cells). In the absence of all 
compounds, both cell lines formed colonies after 13 days. The addition of YC-1, G3, and 
CJ-3-60 (0.1-10 µM) to the culture medium significantly inhibited colony formation of 
MDA MB 231 and JygMC(A). * indicates p < 0.05 when compared to the control. 
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Figure 5-2. Continued. 
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CHAPTER 6.    POSSIBLE MECHANISM OF ANTI-HIF-1α ACTION OF 
NOVEL THERAPEUTIC COMPOUND IN VITRO 
 
 
Introduction 
 
A significant effort has been invested by researchers in identifying and 
developing compounds that inhibit HIF-1α and ascertaining their mechanisms of action. 
None however, at the time of writing this, has been reported that directly and specifically 
targets HIF-1. Although numerous drugs were developed to primarily target signal 
transduction proteins, these drugs were later discovered to inhibit HIF-1 either in 
conjunction with, or as a consequence of inhibiting their primary target [19, 20, 118-122]. 
It has been therefore difficult for researchers to attribute any anti-cancer effects of these 
compounds specifically to the inhibition of HIF-1α due to this lack of specificity. 
Nevertheless, this should not exclude such compounds as potential anticancer agents, 
because the fact that they target multiple pathways makes them very essential if these 
other targets are also implicated in tumourigenesis.  
 
For these studies, we evaluated the molecular mechanism of action of the G3 and 
CJ-3-60. The low levels of HIF-1α observed in the preceding studies may be due to 
impairment in protein translation or an increase in its degradation. Since hypoxia is 
associated with decreased degradation of HIF-1α, and YC-1 in part facilitates in HIF-1α 
degradation, it therefore makes degradation primarily the first possible mechanism of 
action by these analogues to be investigated. Furthermore, since HIF-1 regulation 
characteristically occurs at the protein level, we investigated by western blotting whether 
the compounds had a direct effect on the rate of HIF-1α protein degradation.  
 
Protein hydroxylation induces the proteasomal degradation of HIF-1α on proline 
residues 402 and 564 by specific HIF-prolyl hydroxylases in the presence of iron and 
oxygen [18]. To test whether protein hydroxylation is involved in G3 and 
CJ-3-60-induced inhibition of HIF-1α, a prolyl hydroxylase (PHD) inhibitor 
Dimethyloxalylglycine (DMOG) was used in G3 and CJ-3-60-treated cells under 
normoxia. The protein level of HIF-1α subunit is post-transcriptionally regulated by 
prolyl and asparaginyl hydroxylase (PAH), and suppression of PAH activity increases 
endogenous HIF-1α levels. DMOG is an ester of N-oxalylglycine that penetrates cells 
readily, inhibits all prolyl-4-hydroxylase domain 1–3 factor-inhibiting HIF enzymes, 
thereby upregulating HIF [123,124]. 
 
 
Materials and Methods 
 
 MDA-MB-231 cells were incubated under hypoxia condition for 18 hr in the 
absence or presence or absence of G3 and CJ-3-60 (20 µM) and then treated with 
cycloheximide (30 µM) (CHX) -a protein translation inhibitor- for 15or 30 mins to 
prevent de novo HIF-1α protein synthesis in cells. Western blotting for HIF-1α protein 
was performed as described earlier.  
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In a follow up experiment, cells were pretreated with DMOG (1000 µM) and 
treated either with or without drug (50 µM) for 24 hr under normoxia condition. Cell 
lysates were prepared and subjected to western blotting for HIF-1α. 
 
 
Result 
 
The protein level of HIF-1α was decreased in G3 and CJ-3-60-treated cells in 
comparison with untreated control (Figure 6-1), indicating that G3 and CJ-3-60 
accelerates the degradation process of HIF-1α under hypoxia condition in MDA-MB-231 
cells. 
 
Prior to these experiments, we confirmed that DMOG treatment resulted in a 
stable increase of functionally active HIF-1α proteins in vitro (result not shown). A 
treatment for 24 hr with 1000 µM DMOG resulted in ~ 10.5-fold increase of HIF-1α 
protein levels and similar to results obtained with cells exposed to hypoxia (0.5% O2) for 
the same period of time. Subsequently, we then examined the effect of DMOG, a 
competitive inhibitor for HIF-1α prolyl-hydroxylase (Figure 6-2).  
 
While treatment of the cells with DMOG induced accumulation of HIF-1α under 
normoxic conditions, the induction of HIF-1α was not observed in the presence of either 
G3 or CJ-3-60 without DMOG under normoxia. However, DMOG recovered HIF-1α 
accumulation suppressed by G3 and CJ-3-60 in MDA-MB-231cells under normoxia 
(Figure 6-2). Thus, these results suggest that the inhibition of HIF-1α protein expression 
is caused by degradation of HIF-1α protein and since DMOG recovered HIF-1α 
accumulation inhibited by G3 and CJ-3-60, prolyl hydroxylation is involved in inhibition 
of HIF-1α. 
 
 
Conclusion 
 
In these assays, the inhibitory mechanism of CJ-3-60 was investigated on HIF-1α 
stability in MDA-MB-231cells. All compounds promoted hypoxia-induced HIF-1α 
degradation and cycloheximide (CHX) blocked de novo protein synthesis in MDA-MB-
231 cells. Also, as anticipated, CJ-3-60 had more potency in causing the rapid 
degradation of hypoxia-induced HIF-1α expression than YC-1and G3. 
 
Degradation occurs when HIF-1α is hydroxylated at Pro 564 and Pro 402 located 
at its oxygen-dependent degradation domain (ODDD).This process is facilitated by a 
family of prolyl hydroxylases (PHDs) that require oxygen, iron, and 2-oxoglutarate as the 
co substrate to hydroxylate the specific amino acid residues [125-127]. PHD proteins are 
inhibited in hypoxic conditions, leading to a gradual increase in HIF-1α protein levels 
and formation of the active HIF-1 [128, 129]. 
 
A prolyl hydroxylase (PHD) inhibitor dimethyloxalylglycine (DMOG) is usually 
utilized to examine whether prolyl hydroxylation is involved in inhibition of HIF-1α  
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Figure 6-1. Effect of drugs on hypoxia-induced HIF-1α protein stability by 
post-translational modification in MDA-MB-231 cells. 
 
Cells were incubated under hypoxia condition for 18 h in the absence or presence of YC-
1, G3, and CJ-3-60 (20 µM) and then treated with cycloheximide (CHX) (30 µM) for 15 
or 30 min. Cell lysates were prepared and subjected to western blotting for HIF-1α (a). 
Quantified graphs of HIF-1α normalize with levels of actin (b). * indicates p < 0.05 when 
compared to untreated hypoxia sample and # indicates p < 0.05 when compared to 15 
mins respective reoxygenated samples and untreated hypoxia  
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Figure 6-2. Inhibitory effect of G3 and CJ-3-60 on HIF-1α accumulation via 
prolyl hydroxylation under normoxia. 
 
Cells were pretreated with DMOG (1000 µM) and treated either with or without 
respective drug (50 µM) for 18 hr under normoxia or hypoxia condition. Cell lysates 
were prepared and subjected to western blotting for HIF-1α. (a) Western blot analysis. (b) 
quantified graphs. 
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accumulation. Here, DMOG recovered HIF-1α accumulation suppressed by these drugs 
in MDA-MB-231 cells under normoxia, which indicates that these drugs may be acting as 
agonists of the enzymes (prolyl hydroxylases) involved in physiologic degradation of 
HIF-1α. In vitro screenings of chemical libraries conducted for such agonists of the 
enzymes implicated in HIF-1α degradation (three prolyl hydroxylases, PHD1-3 and 
acetyltransferase, ARD1), have suggested that, alternatively, such drugs may activate 
PHDS by reversing fumerate or succinate-mediated inhibition of PHDS [130, 131]. 
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CHAPTER 7.    POSSIBLE MECHANISM OF ANTI-METASTATIC ACTION OF 
NOVEL THERAPEUTIC COMPOUND IN VITRO 
 
 
Introduction 
 
 
Effect of Compounds on the Expression of Hypoxia-Induced HEF1 
Expression 
 
Hypoxia in the tumor microenvironment enhances cancer progression by 
triggering adaptive programs that promote cell survival, motility, and tumor 
angiogenesis. Many cellular responses to hypoxia are mediated through changes in gene 
expression. Human Enhancer of Filamentation protein 1 (HEF1), also known as Neural 
precursor cell Expressed Developmentally Down-regulated protein 9 (NEDD9), is part of 
the Cas family of proteins, which include HEF1/NEDD9, p130Cas and Efs. HEF1 is a 
docking protein that plays a central coordinating role related to cell adhesion, motility, 
growth and apoptosis [132, 133]. It is believed to be one of the chief regulator of cancer 
metastasis, essential for the invasive activity of certain cancer cells [134] and is linked to 
the promotion of metastasis in some others [135].Studies have suggested that HEF1 is an 
essential regulator for metastasis of melanoma and glioblastoma [133, 134], and 
overexpression of HEF1 advances cancer cell growth, migration, and invasion through 
the activation of various signal transduction pathways [136-139]. 
 
 
Effect of Compounds on the Expression of MMP-9 in MDA-MB-231 
Cells 
 
Hypoxia is widely being proposed as another regulator of HEF1 expression. In 
one study, HEF1 was upregulated after transient global ischemia in rats [140], and in 
cultured mesenchymal stem cells in response to hypoxia [141]. However, the molecular 
basis for regulation and function of HEF1 in cancer tissues under hypoxic conditions 
remains largely unknown [140]. HIF-1α has been shown to stimulate HEF1 transcription 
when colon carcinoma cells were exposed to hypoxia. Inhibition of HEF1 expression has 
been reported to be linked to reduced levels of hypoxia-inducible genes, including those 
that regulate cell motility. Furthermore, inhibition of HIF-1α by its siRNA blocked 
hypoxia-induced HEF1 expression at both the protein and mRNA levels. Treatment of 
CoCl2, a chemical inducer of HIF-1α, increased HEF1 protein levels [142]. 
 
Various studies have suggested that HIF-1α stimulates tumor cell invasiveness 
under hypoxic conditions in vitro by regulating genes including those involved in 
extracellular matrix metabolism (MMPs) [144,145]. Matrix Metallo-Proteinases (MMPs) 
are a family of enzymes involved in degradation of extracellular matrix (gelatinases, 
collagenases) and are vital in tissue remodeling during tumor invasion, metastasis, and 
angiogenesis. The MMP-9 (a member of the MMP family) is a known mediator of tumor 
cell invasion [146] and has recently been shown to be critical for the invasive steps of 
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metastasis [147-148], the fact that its expression correlates with HIF-1α expression 
suggests that HIF-1α is involved in promoting MMP-9-dependent metastasis. As a result 
of this, we tested whether compounds could inhibit the expression of MMP-9 in MDA-
MB-231 cells by western blot assay. 
 
 
Materials and Methods 
 
 
Luciferase Assay 
 
For dual luciferase reporter assays, 6 x 104 MDA-MB-231 cells were plated on 
24-well tissue culture plate. The following day, they were co-transfected with 0.5455µg 
firefly luciferase reporter constructs pHEF1-Luc and 0.0545 µg of the control Renilla 
luciferase reporter phRluc-TK using the nonliposomal transfection reagent, Fugene 
6(Promega). After treatment, cells were lysed with cell lysis buffer provided by the dual-
luciferase reporter assay kit (Promega). Luciferase activity was then measured according 
to the manufacture's instruction. 
 
 
Western Blot Analysis 
 
MDA-MB-231 cells were treated for 24 hr with various concentrations of YC-1, 
G3, and CJ-3-60 (1, and 10 µM) and collected. The cells were then lysed as described 
earlier for western blot assay The blots were incubated with specific antibodies against 
MMP-9 (1:1000, Santa Cruz) overnight at 4oC followed by Li-COR conjugated 
secondary anti mouse antibody for 1 hr at 37 o C. Detection was performed by the 
Odyssey Infrared Imaging System (Li-COR Inc., Lincoln, Massachusetts). The blot was 
reprobed with polyclonal anti-actin antibody to ascertain equal loading of proteins. 
 
 
Result 
 
 
Novel Compound Inhibits Hypoxia-Induced HEF1 Expression 
 
 Studies have revealed the relevance of HEF1 in metastasis, although the precise 
mechanism of action requires further investigation. Furthermore, no serious attempt has 
as yet been made to target HEF1 for drug development; therefore since HIF-1α is a 
critical transcription factor in regulating the cellular transcriptional response to hypoxia 
[143], we examined whether compounds inhibits cell migration by inhibiting the 
hypoxia-induced expression of HEF, which is mediated by HIF-1α. As shown in  
Figure 7-1, MDA-MB-231 cells treated with novel compounds and a known HIF-1α 
inhibitor, YC-1, inhibits hypoxia-induced HEF1 expression. 
 
  
  61 
 
 
 
Figure 7-1. Compounds inhibit hypoxia-induced HEF1 expression. 
 
MDA-MB-231 cells were transiently co-transfected with pHEF1-Luc and phRluc-TK 
plasmids for 48 hr while under drug treatment, and exposed to hypoxia for the last 18 hr. 
The luciferase activity was then determined. Luciferase activity represents data that have 
been normalized into cotransfected Renilla luciferase activity, then quantified as a ratio 
of expression levels from normoxia samples. * indicates p < 0.05 when compared to the 
hypoxia untreated control. # indicates p < 0.05 when compared to YC-1 at the same 
concentration. 
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Compound Suppresses the Activity and Expression of MMP-9 in 
MDA-MB-231 Cells 
 
Breast cancer cells produce MMPs, and its increased expression is associated with 
disease progression [149]. The activity and expression of MMP-9 in MDA-MB-231cells 
exposed to different concentrations of YC-1, G3, and CJ-3-60 were examined to explore 
the possible anti invasive mechanism of the compounds. Western blotting analysis was 
carried out to examine the expression of MMP-9 in MDA-MB-231 cells. YC-1, G3, and 
CJ-3-60 exerted inhibitive effect on the expression of MMP-9 in a 
concentration-dependent manner compared with the control group (Figure 7-2a). 
Quantification analysis indicated that MMP-9 activity reduced by 42%, 52% and 76% 
when cells were treated with 10 µM of YC-1, G3, and CJ-3-60 (Figure 7-2b). 
 
 
Conclusion 
 
 Over the years, our understanding of metastasis has progressed considerably. 
However, a lot still needs to be elucidated about this significant process for the 
advancement of cancer treatment. Alterations in expression of HEF1/CAS-L/NEDD9 
protein, have been established over the past decade to be a strong pro-metastatic stimulus 
in numerous cancers, and reportedly important in regulating genes that are fundamentally 
involved in cell motility such as MMP9 [150, 151], and apoptosis [152-155]. CJ-3-60 
inhibited, in MDA-MB- 231 cancer cells, the expression and secretion of, MMP-9, which 
is involved in the degradation of extracellular matrix and play vital roles in cancer cell 
migration and invasion [156-158]. The complex multistep process of metastasis of cancer 
cells involves cell adhesion, invasion and motility, therefore interruption of one or more 
of these steps can be considered as one approach for anti-metastatic therapy [124].  
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Figure 7-2. CJ-3-60 reduced the protein levels of MMP 9 in MDA-MB-231 under 
hypoxic conditions in a dose-dependent manner. 
 
Western blot analysis of YC-1, G3, and CJ-3-60 in the downregulation of MMP-9 
expression in MDA-MB-231 cells shows that all compounds could inhibit the MMP-9 
expression in a concentration-dependent manner (a). Quantification of the western blot 
assay with protein levels of MMP-9 normalized with levels of actin (b). *P < 0.05 
compared with control. Data are presented as the mean ± SE of two separate experiments. 
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CHAPTER 8.    FUTURE PRECLINICAL STUDIES 
 
 
In order to survive and proliferate, cancer cells must adapt to the hypoxic 
environment [159]. Hypoxic tumors cells undertake several morphological and genetic 
alterations including angiogenesis, anaerobic glycolysis, and production of stress proteins 
associated with their survival or death [20, 160, 161]. The heterogeneity of the human 
cancer observed in any particular individual over time, and between individuals with the 
same type of cancer is the greatest impediment to the establishment of potent therapies 
for this disease. Despite the discovery of numerous genetic and epigenetic alterations in 
cancer cells, understanding which of these alterations represent critical therapeutic targets 
in a particular patient still proves to be a major challenge. The central role of HIF-1α in 
the adaptive response to hypoxia and in the activation of numerous pathways responsible 
for tumor progression, positions it as a viable target for anticancer drug development. The 
potential of HIF-1α as a target for cancer therapy, therefore, lies in the development of 
small molecule inhibitors of HIF-1 [160-162]. 
 
The recognition that HIF-1 plays a key role in cancer biology and the improved 
understanding of the roles and regulatory mechanisms induced by this transcription factor 
will open the gate to novel, potentially effective and selective therapies against a variety 
of pathologic conditions, such as ischemic/hypoxic injuries, tumor growth, and 
cardiovascular remodeling. Based on the rapidly growing interest in therapeutic strategies 
targeting hypoxia/HIF, more active compounds of potential interest for preclinical trial 
will undoubtedly be generated. However, one issue pertinent to the development of 
anti-HIF compounds is that HIF-1 inhibition alone may be insufficient in arresting 
angiogenesis and tumor growth, because HIF independent pathways may circumvent or 
overcome HIF inhibition [162-164]. Therefore, due to the possibility that HIF-1 
inhibitors may have limited activity when used as single agents, combining HIF 
inhibitors with conventional therapies or prospective molecular targeted agents may be 
necessary.  
 
We set out, using various experimental methods, to discover of HIF-1 inhibitors 
through a cell-based HTS, which has provided some information regarding novel 
compounds that impede some pathways involved in HIF-1 regulation. In our quest for 
finding potential therapeutics, we choose YC-1 as a basic scaffold. Based on the premise 
that the synthesis of YC-1 derivatives should be an active area of research, hundreds of 
small molecule compounds were screened, and several showed positive and potent 
anti-HIF-1α activity at the initial screening round. We discovered that G3, an existing 
analogue of YC-1, affects the hypoxic accumulation of HIF-1α protein more potently 
when compared to YC-1 We further validated the potency of the newly discovered 
compound and performed comparison analyses. This was therefore selected as a 
structural scaffold to design novel compounds, one of which, CJ-3-60, displayed an 
impressive result. Also after selecting the most potent drug moieties, we examined their 
effect on other members of the HIF family and other genes with functional roles similar 
or complementary to HIF-1.  
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The in vitro studies showed that G3 and CJ-3-60 was able to decrease the 
accumulation of hypoxia-inducible factor (HIF-1α) and the expression of downstream 
HIF-1 target genes, including those for vascular endothelial growth factor. Although 
HIF-1α down-regulation may be insufficient for HIF-1 inhibition, we propose developing 
G3 and CJ-3-60 as a novel attractive therapeutic agent aimed to inhibit angiogenesis and 
breast cancer therapeutic agent for cancer cells.  
 
While the compounds are designed to target a specific biological molecule (HIF 
1α), we elucidated important mechanisms of the anticancer activity of G3 and CJ-3-60, 
related to cell survival and angiogenesis, which are essential for the adaptation of cancer 
cells to micro environmental hypoxia and hence for tumor progression. These 
mechanisms may in part explain the broad spectrum of the novel compound’s anticancer 
effects, and provide a rationale for its development as an anticancer drug. Any anti HIF-1 
compound may disrupt the HIF-1 signaling pathway through a variety of mechanisms. 
Therefore in terms of the anti-HIF mechanism of G3 and CJ-3-60, some mechanisms may 
still need to be explored, since the HTSS does not reveal mechanisms of action of anti-
HIF-1α compounds. Hence, more studies on the mechanism of action of G3 and CJ-3-60 
will likely provide new insights into its validity/applicability for the pharmacologic 
targeting of HIF-1α for therapeutic purposes. 
 
We anticipate that some of these compounds identified in this approach will 
progress through the preclinical models, and tested for further clinical development. 
Preclinical efficacy of the therapy will eventually be evaluated with the primary end point 
of overall survival and safety, while the secondary end points will include tumor size 
decline and inhibition or reduction in metastasis. Further work is ongoing in our lab to 
identify more selective HIF-1 inhibitors, to determine their mechanism of action and to 
translate these developments into clinical trials. The most potent drug candidates with the 
highest HIF-1α specificity and selectivity and minimal side effect will be used for 
subsequent studies. We envisage that results from these screens will lead to an increase in 
the number of HIF inhibitors over in the near future, and likely reveal novel targets 
involved in the regulation of HIF activity. The further investigation of these positive 
“hits” in significant preclinical models and the modified early clinical trials is crucial for 
maximizing the results of this exciting area of drug development.  
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